VIVUS Announces Issuance of Two Key U.S. Patents for Qsymia; Patent Coverage for Qsymia Extended to 2029
November 13, 2013 07:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Nov. 13, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV...
VIVUS Announces Scientific Presentations
November 12, 2013 08:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV...
VIVUS to Present at Upcoming Investor Conference
November 12, 2013 07:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that management will present an overview of the company at the following investment...
VIVUS Reports Third Quarter and First Nine Months 2013 Financial Results
November 05, 2013 16:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV...
VIVUS Announces Date of Third Quarter 2013 Financial Results and Conference Call
November 01, 2013 16:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Nov. 1, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the third quarter ended September 30, 2013 after the NASDAQ...
Newly Published Study Finds Qsymia Achieves Greater Weight Loss at Lower Doses Than Either of Its Components as Monotherapy
October 31, 2013 07:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) announced today that a newly-published study demonstrated Qsymia® (phentermine and topiramate extended-release)...
VIVUS, Inc. Announces License Agreement for the Marketing Rights to STENDRA in the United States and Canada
October 11, 2013 07:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Oct. 11, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced the signing of an agreement providing Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL) the exclusive...
Qsymia Shown to Reduce Progression to Type 2 Diabetes in High-Risk Overweight or Obese Patients
October 08, 2013 18:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Oct. 8, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced new data published online in Diabetes Care demonstrating the effects of Qsymia® (phentermine and...
Peter Y. Tam Resigns as VIVUS President
September 27, 2013 17:15 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Sept. 27, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) the "Company") today announced that Peter Y. Tam will resign as president effective October 12, 2013.
During his...
VIVUS Updates European Filing Strategy for Qsiva
September 20, 2013 07:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Sept. 20, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced it has submitted to the European Medicines Agency (EMA) a request for scientific advice regarding...